Pharmobedient Drug Patent Portfolio
Pharmobedient owns 3 orange book drugs protected by 4 US patents Given below is the list of Pharmobedient's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6702997 | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma | 28 Dec, 2021 | Expired |
| US6632842 | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease | 28 Dec, 2021 | Expired |
| US5980867 | Flunisolide aerosol formulations | 06 Jul, 2018 | Expired |
| US5776433 | Flunisolide aerosol formulations | 07 Jul, 2015 | Expired |
Latest Legal Activities on Pharmobedient's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Pharmobedient.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| File Marked Found | 03 Jul, 2019 | US6702997 |
| File Marked Found | 17 Oct, 2018 | US6632842 |
| File Marked Found | 02 Oct, 2018 | US6702997 |
|
Correspondence Address Change
Critical
| 13 Jun, 2014 | US6702997 |
|
Correspondence Address Change
Critical
| 20 May, 2004 | US6632842 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 06 May, 2004 | US6702997 |
|
Correspondence Address Change
Critical
| 06 May, 2004 | US6702997 |
| Post Issue Communication - Certificate of Correction | 26 Mar, 2004 | US6702997 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 09 Mar, 2004 | US6702997 |
|
Recordation of Patent Grant Mailed
Critical
| 09 Mar, 2004 | US6702997 |
|
Issue Notification Mailed
Critical
| 19 Feb, 2004 | US6702997 |
| Receipt into Pubs | 30 Jan, 2004 | US6702997 |
|
Application Is Considered Ready for Issue
Critical
| 28 Jan, 2004 | US6702997 |
| Receipt into Pubs | 23 Jan, 2004 | US6702997 |
| Receipt into Pubs | 28 Nov, 2003 | US6702997 |
Pharmobedient's Family Patents
Recent FDA approvals and tentative approvals for Pharmobedient
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Fluoxetine Hydrochloride |
SUPPL-10
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Labeling | 25 May, 2007 |
Pharmobedient Drug List
Given below is the complete list of Pharmobedient's drugs and the patents protecting them.
1. Accuneb
Accuneb is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6702997 | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma |
28 Dec, 2021
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Accuneb's drug page
2. Aerospan Hfa
Aerospan Hfa is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5980867 | Flunisolide aerosol formulations |
06 Jul, 2018
(8 years ago)
| Expired |
| US5776433 | Flunisolide aerosol formulations |
07 Jul, 2015
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aerospan Hfa's drug page
3. Duoneb
Duoneb is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6632842 | Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease |
28 Dec, 2021
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Duoneb's drug page